Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited atlanta arcade church road near leela hotel - rifampicin 150 mg isoniazid 75 mg ethambutol… - film-coated tablet - rifampicin 150 mg isoniazid 75 mg ethambutol… - antimycobacterials: other drugs for treatment of

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rifampicin - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - rifampicin - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - rifampicin - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - rifampicin - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - rifampicin - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - rifampicin - oral capsule - 150mg

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited atlanta arcade church road near leela hotel - rifampicin 150 mg isoniazid 75 mg & pyrazinamide… - film-coated tablet - rifampicin bp 150 mg isoniazid bp 75 mg … - antimycobacterials: combinations of drugs for

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 150mg - capsule - 150 mg - active: rifampicin 150mg excipient: magnesium stearate maize starch - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - rifampicin 150 mg - capsule, hard - 150 mg - rifampicin 150 mg - rifampicin